Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Prevnar 13 in Healthy Infants
NCT00444457Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2007
- Primary completion
- Jun 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 13 in pneumococcal disease (4 arms), sponsored by Pfizer. Primary endpoints: Geometric Mean Concentration for Serotype-specific Pneumococcal IgG Antibody, Percentage of Participants Achieving Antibody Level ≥0.1 IU/mL for Tetanus Toxoid and 2 more. Started May 2007; status: completed.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT00444457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00444457.